论文部分内容阅读
目的探讨奥沙利铂(L-OHP)联合5-氟脲嘧啶(5-Fu)、亚叶酸钙(CF)组成的FOLFOX4方案治疗晚期胃癌的客观疗效。方法128例晚期胃癌患者随机分为两组进行联合化疗,其中FOLFOX4方案组(A组)66例,ELF方案组(B组)62例,对A、B两组的疗效、主要副反应及生存期(OS)进行比较。结果A组有效率为54.7%,中位OS12.8月,中位疾病进展时间(TTP)6.8个月;B组有效率为35.0%,中位OS10.1个月,中位TTP 5.6个月。A组有效率明显高于B组(P<0.05);A组中位OS、中位TTP与B组比较,无显著差异。结论FOLFOX4方案治疗晚期胃癌疗效肯定,毒副反应轻,患者耐受性好,值得临床进一步扩大研究。
Objective To investigate the objective effect of oxaliplatin (L-OHP) combined with 5-fluorouracil (5-Fu) and leucovorin (CF) on FOLFOX4 regimen in advanced gastric cancer. Methods A total of 128 patients with advanced gastric cancer were randomly divided into two groups: combination chemotherapy, 66 cases in group FOLFOX4 (group A) and 62 cases in group ELF (group B). The curative effect, main side effects and survival Period (OS) for comparison. Results The effective rate in group A was 54.7%, the median OS12.8 months, the median time to progression of disease (TTP) 6.8 months; the effective rate in group B was 35.0%, the median OS was 10.1 months, and the median TTP was 5.6 months . The effective rate of group A was significantly higher than that of group B (P <0.05). There was no significant difference between group A and group B with median OS and median TTP. Conclusion FOLFOX4 regimen is effective in the treatment of advanced gastric cancer with mild toxicity and good tolerability. It is worth further investigation.